Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Jones

Premium
Isis Pharmaceuticals has appointed Jeffrey Jones as executive vice president.
 
In this position, Jones will lead clinical development, preclinical development, regulatory affairs, and quality assurance and compliance at Isis, the company said.
 
Prior to joining Isis, Jones held various positions at Forest Laboratories, most recently chief medical officer and executive vice president. Before working at Forest, he worked at Upjohn Laboratories as director of psychopharmacology and later chief medical officer and vice president of clinical development.
 
Jones received an MD from Harvard Medical School, Isis said.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.